Randomized placebo-controlled trials in the development of disease-modifying treatments for Alzheimer’s disease are typically of short duration (12–18 months), and health economic modeling requires extrapolation of treatment effects beyond the trial period. (1) Reed, C., Happich, M., Raskin, J. et al…. Continue Reading →

Following the press release issued by Biogen regarding their plans on regulatory filing for Aducanumab in Alzheimer’s disease based on new analysis of larger dataset from Phase 3 studies, we are pleased to announce that these results will be presented… Continue Reading →

New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints Based on discussions with the FDA, the Company plans to submit a Biologics License… Continue Reading →